Changes in the gut microbiota composition and the plasma ghrelin level in patients with<i>Helicobacter pylori-</i>infected patients with eradication therapy

Yanagi, Hidetaka; Tsuda, Ayumi; Matsushima, Masashi; Takahashi, Shunsuke; Ozawa, Genki; Koga, Yuichi; Takagi, Atsushi

doi:10.1136/bmjgast-2017-000182

Cited by 56 publications

(75 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[76][77][78][79] Bismuth-based quadruple therapy was used in two studies. [76][77][78][79][80][81] Shortly after H pylori eradication therapy, the bacterial diversity was significantly reduced at the end of eradication therapy. [76][77][78][79][80][81] Shortly after H pylori eradication therapy, the bacterial diversity was significantly reduced at the end of eradication therapy.…”

Section: Impac T Of H Pylori Er Adic Ation On G Ut MI Crob I Otamentioning

confidence: 99%

“…80,81 The case numbers are relatively small, ranging from 6 to 70, with a total of 147 cases. [76][77][78][79][80][81] In patients treated with triple therapy, the relative abundance of Firmicutes was reduced, whereas that of Proteobacteria was increased. [76][77][78][79][80][81] In patients treated with triple therapy, the relative abundance of Firmicutes was reduced, whereas that of Proteobacteria was increased.…”

Section: Impac T Of H Pylori Er Adic Ation On G Ut MI Crob I Otamentioning

confidence: 99%

“…Six studies assessed the impact of H pylori eradication on the gut microbiota, two of them being published in 2018. [76][77][78][79][80][81] Five of them reported the short-term changes (less than 3 months) and only three of them reported the long-term changes (48 weeks or more). 76,[78][79][80][81] Triple therapy (PPI-amoxicillin-clarithromycin) for 7 days was used in four studies.…”

Section: Impac T Of H Pylori Er Adic Ation On G Ut MI Crob I Otamentioning

confidence: 99%

“…[76][77][78][79][80][81] Five of them reported the short-term changes (less than 3 months) and only three of them reported the long-term changes (48 weeks or more). 76,[78][79][80][81] Triple therapy (PPI-amoxicillin-clarithromycin) for 7 days was used in four studies. [76][77][78][79] Bismuth-based quadruple therapy was used in two studies.…”

Section: Impac T Of H Pylori Er Adic Ation On G Ut MI Crob I Otamentioning

confidence: 99%

“…76,[78][79][80][81] Triple therapy (PPI-amoxicillin-clarithromycin) for 7 days was used in four studies. [76][77][78][79] Bismuth-based quadruple therapy was used in two studies. 80,81 The case numbers are relatively small, ranging from 6 to 70, with a total of 147 cases.…”

Section: Impac T Of H Pylori Er Adic Ation On G Ut MI Crob I Otamentioning

confidence: 99%

See 4 more Smart Citations

Review: Treatment of Helicobacter pylori Infection 2019

et al. 2019

View full text Add to dashboard Cite

This review summarizes important studies regarding Helicobacter pylori therapy published from May 2018 to May 2019. The main themes that emerge involve studies assessing the efficacy of bismuth‐based regimens. While in recent years the efficacy of bismuth‐based quadruple therapy as a second‐line therapy has been clearly established, there is now substantial evidence that it is the best performing first‐line therapy. Antibiotic resistance was again intensely studied this year, and a clear and dramatic increase in resistance is noted for clarithromycin and levofloxacin; most notably, it may not be possible to support these therapies in most regions of the world much longer without testing. The utility of vonoprazan as an alternative to proton‐pump inhibitor therapy, especially in resistant and difficult to treat groups, has also been considered in greater detail this year, as well as means of supporting and enhancing adherence to therapy. Several studies showed that the diversity of gut microbiota was significantly altered shortly after H pylori eradication. However, the diversity was restored to pre‐treatment state after 2 months in patients treated with triple therapy. More studies are warranted to assess the long‐term changes of gut microbiota after H pylori eradication.

show abstract

Section: Impac T Of H Pylori Er Adic Ation On G Ut MI Crob I Otamentioning

confidence: 99%

Section: Impac T Of H Pylori Er Adic Ation On G Ut MI Crob I Otamentioning

confidence: 99%

Section: Impac T Of H Pylori Er Adic Ation On G Ut MI Crob I Otamentioning

confidence: 99%

Section: Impac T Of H Pylori Er Adic Ation On G Ut MI Crob I Otamentioning

confidence: 99%

Section: Impac T Of H Pylori Er Adic Ation On G Ut MI Crob I Otamentioning

confidence: 99%

See 3 more Smart Citations

Review: Treatment of Helicobacter pylori Infection 2019

et al. 2019

View full text Add to dashboard Cite

show abstract

Western Diet Changes Gut Microbiota and Ameliorates Liver Injury in a Mouse Model with Human‐Like Bile Acid Composition

et al. 2021

View full text Add to dashboard Cite

Western-style high-fat/high-sucrose diet (HFHSD) changes gut microbiota and bile acid (BA) profiles. Because gut microbiota and BAs could influence each other, the mechanism of changes in both by HFHSD is complicated and remains unclear. We first aimed to clarify the roles of BAs in the HFHSD-induced change of gut microbiota. Then, we studied the effects of the changed gut microbiota on BA composition and liver function. Male wild-type (WT) and human-like Cyp2a12/Cyp2c70 double knockout (DKO) mice derived from C57BL/6J were fed with normal chow or HFHSD for 4 weeks. Gut microbiomes were analyzed by fecal 16S ribosomal RNA gene sequencing, and BA composition was determined by liquid chromatography-tandem mass spectrometry. The DKO mice exhibited significantly reduced fecal BA concentration, lacked muricholic acids, and increased proportions of chenodeoxycholic and lithocholic acids. Despite the marked difference in the fecal BA composition, the profiles of gut microbiota in the two mouse models were quite similar. An HFHSD resulted in a significant increase in the BA pool and fecal BA excretion in WT mice but not in DKO mice. However, microbial composition in the two mouse models was drastically but similarly changed by the HFHSD. In addition, the HFHSD-induced change of gut microbiota inhibited BA deconjugation and 7α-dehydroxylation in both types of mice, which improved chronic liver injury observed in DKO mice. Conclusion:The HFHSD itself causes the change of gut microbiota due to HFHSD, and the altered composition or concentration of BAs by HFHSD is not the primary factor. On the contrary, the gut microbiota formed by HFHSD affects BA composition and ameliorates liver injury in the mouse model with human-like hydrophobic BA composition. (Hepatology Communications 2021;0:1-16).

show abstract

Implications of the Gut Microbiome in Parkinson's Disease

et al. 2020

View full text Add to dashboard Cite

Parkinson's disease is a common neurodegenerative disorder that presents with nonmotor and motor symptoms. The nonmotor manifestations of Parkinson's disease often begin years before the motor symptoms. Autopsy studies, including both Parkinson's disease patients and matched controls, demonstrated that α‐synuclein aggregates in Parkinson's disease patients can be found in both the substantia nigra and the enteric nervous system. Therefore, it has been hypothesized that the pathological process that leads eventually to Parkinson's disease might initially take place in the enteric nervous system years before the appearance of motor features. The gut microbiome plays essential roles in the development and maintenance of different body systems. Dysbiosis of the normal gut microbiome is thought to be associated with pathophysiologic changes not only in the gastrointestinal system itself but also in the enteric and central nervous systems. These changes are thought to ultimately cause loss of dopaminergic neurons via various mechanisms including the release of neurotoxins into the systemic circulation, decreased production of neuroprotective factors, and triggering inflammatory and autoimmune responses. In this review, we review the gut microbiome changes in Parkinson's disease and discuss the mechanisms by which gut microbiome dysbiosis may be a contributing factor to the pathophysiology of Parkinson's disease. © 2020 International Parkinson and Movement Disorder Society

show abstract

Changes in the gut microbiota composition and the plasma ghrelin level in patients withHelicobacter pylori-infected patients with eradication therapy

Cited by 56 publications

References 25 publications

Review: Treatment of Helicobacter pylori Infection 2019

Review: Treatment of Helicobacter pylori Infection 2019

Western Diet Changes Gut Microbiota and Ameliorates Liver Injury in a Mouse Model with Human‐Like Bile Acid Composition

Implications of the Gut Microbiome in Parkinson's Disease

Contact Info

Product

Resources

About